Jeffrey Riney, MD
Family Medicine · Paducah, KYNPI 1669495552
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 268 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$763
- AstraZeneca$566
- Pfizer$558
- AbbVie$436
- Lilly USA, LLC$316
- Amgen$217
- plus $2K from 24 others
Across 3 payments — averaging $14,994 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$45K
What the payments were for
- Food & beverage$4,368100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $763 |
| AstraZeneca | 36 | $566 |
| Pfizer | 32 | $558 |
| AbbVie(2 entities) | 26 | $436 |
| Lilly USA, LLC | 19 | $316 |
| Amgen(2 entities) | 13 | $217 |
| Sanofi-aventis U.S. LLC | 11 | $174 |
| Bayer | 9 | $152 |
| Johnson & Johnson | 8 | $121 |
| E.r. Squibb & Sons, L.L.C. | 8 | $106 |
| Novartis | 7 | $105 |
| Exact Sciences | 6 | $103 |
| Astellas Pharma US Inc | 6 | $97 |
| Eisai Inc. | 4 | $81 |
| Dexcom, Inc. | 4 | $70 |
| GSK | 3 | $63 |
| Almatica Pharma LLC | 3 | $60 |
| Kowa Pharmaceuticals America, Inc. | 4 | $57 |
| Boehringer Ingelheim | 4 | $54 |
| Merck | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Biogen | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $24 |
| Corium, LLC | 1 | $22 |
| Insulet Corporation | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Antares Pharma, Inc. | 1 | $11 |
How this compares
$4,368 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 148 | $162,297 |
| FarxigaDapagliflozin Propanediol | 98 | $85,835 |
| OzempicSemaglutide | 51 | $58,682 |
| RybelsusSemaglutide | 34 | $43,300 |
| XareltoRivaroxaban | 47 | $38,342 |
| JardianceEmpagliflozin | 40 | $30,964 |
| PercocetOxycodone Hcl/Acetaminophen | 11 | $27,297 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $22,535 |
| MounjaroTirzepatide | 20 | $22,149 |
| TrulicityDulaglutide | 15 | $20,203 |
| LinzessLinaclotide | 11 | $12,025 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,602 |
| Repatha SureclickEvolocumab | 15 | $8,309 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,394 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $558 | $166,174159 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $566 | $102,284130 claims |
| Novo NordiskOzempic, Rybelsus | $763 | $101,98285 claims |
| Lilly USA, LLCMounjaro, Trulicity | $316 | $42,35235 claims |
| Johnson & JohnsonXarelto | $121 | $38,34247 claims |
| Boehringer IngelheimJardiance | $54 | $30,96440 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $174 | $22,53515 claims |
| AbbVieLinzess, Synthroid | $436 | $15,41365 claims |
| GSKBreo Ellipta | $63 | $7,39417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Paducah
- James TurnboPaducah$124K
- James EickholzPaducah$14K
- Isaac MittendorfPaducah$11K
- Christopher RhyneLouisville$933K
- John RichardLexington$226K
- Edward SchumannFlorence$79K
- Ronald KoffNew Castle$71K
- Suraj GathaniLouisville$69K
- Bradley GrayFlorence$51K
- Jackie KazeeAshland$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.